• Français

Wednesday, May 26 2010
Press release

The Quebec Consortium for Drug Discovery (CQDM) awards a Sainte-Justine University Hospital Center innovative research project

A project selected for an investment of almost $2M

In its latest competition, the Quebec Consortium for Drug Discovery (CQDM) awarded a Sainte-Justine University Hospital Center innovative research project. This new technology paves the way toward developing novel oral medications that will be more effective and cause fewer adverse reactions than the drugs that are presently available.

This technological platform, known as Module Z, was developed by Dr. Sylvain Chemtob, a neonatologist and researcher in the Sainte-Justine University Hospital Research Center Fetomaternal Pathologies axis. The platform will make it possible to develop within a very short time modulators that act on precise targets within the cell (e.g., enzymes, receptors). For the pharmaceutical industry, this offers promising opportunities to develop medications that are much more effective and safe for various pathologies, including inflammatory diseases such as rheumatoid arthritis, diabetes-related complications and possibly even neurodegenerative diseases.

The research projects went through a rigorous assessment process that involved, among other things, an independent panel of scientific and industrial experts organized by the Fonds de la recherche en Santé du Québec (FRSQ), and a risk analysis carried out by the CQDM. The selected projects include high-caliber researchers who are world leaders in their respective fields.

Dr. Chemtob’s achievements are the result of many years of work and represent an exceptional example of knowledge being transferred from the laboratory to the patient’s bedside. Through innovative projects of this nature the Sainte-Justine University Hospital Research Center continues to promote mother-child health in Quebec.

The CQDM is a non-profit organization that meets the needs of the pharmaceutical industry by helping to accelerate the discovery of new medications and the development of safer and more effective drugs. Funding comes directly from its public and private partners, the FRSQ, the Quebec Ministry of Economic Development, Innovation and Export Trade (MDEIE), the Networks of Centres of Excellence (NCE), Pfizer Canada, AstraZeneca Canada and Merck.

– 30 –

For information

Nicole Saint-Pierre
Sainte-Justine University Hospital Research Center
514 345-4931 poste 2555

About this page
Updated on 9/9/2014
Created on 6/19/2014
Alert or send a suggestion

Every dollar counts!

Thank you for your generosity.

It is thanks to donors such as you that we are able to accelerate research discoveries, to heal more children every year and to continue to offer world-class care.

It is also possible to give by mail or by calling toll-free

1-888-235-DONS (3667)

Contact Us

514 345-4931


© 2006-2014 CHU Sainte-Justine.
All rights reserved. 
Terms of Use,  Confidentiality,  Security


All information contained within the CHU Sainte-Justine site should not be used as a substitute for the advice of a duly qualified and authorized medical practitioner or any other health professional. The information provided on this site is intended for educational and informational purposes only.

Consult your physician if you feel ill or call 911 for any medical emergency.

CHU Sainte-Justine